يعرض 1 - 10 نتائج من 204 نتيجة بحث عن '"Biolato, M."', وقت الاستعلام: 1.38s تنقيح النتائج
  1. 1
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
  6. 6
    دورية أكاديمية

    المساهمون: Lucidi, C., Biolato, M., Lai, Q., Lattanzi, B., Lenci, I., Milana, M., Lionetti, R., Liguori, A., Angelico, M., Tisone, G., Avolio, A. W., Agnes, S., Rossi, M., Grieco, A., Merli, M.

    مصطلحات موضوعية: cancer, complication, liver transplant, neoplasms

    الوصف: Background: Recent innovations in the field of liver transplantation have led to a wealth of new treatment regimes, with potential impact on the onset of de novo malignancies (DNM). The aim of this multicenter cohort study was to provide contemporary figures for the cumulative incidences of solid and hematological DNM after liver transplantation. Methods: We designed a retrospective cohort study including patients undergoing LT between 2000 and 2015 in three Italian transplant centers. Cumulative incidence was calculated by Kaplan–Meyer analysis. Results: The study included 789 LT patients with a median follow-up of 81 months (IQR: 38–124). The cumulative incidence of non-cutaneous DNM was 6.2% at 5-years, 11.6% at 10-years and 16.3% at 15-years. Post-Transplant Lymphoproliferative Disorders (PTLD) were demonstrated to have a cumulative incidence of 1.0% at 5-years, 1.6% at 10-years and 2.2% at 15-years. Solid Organ Tumors (SOT) demonstrated higher cumulative incidences – 5.3% at 5-years, 10.3% at 10-years and 14.4% at 15-years. The most frequently observed classifications of SOT were lung (rate 1.0% at 5-years, 2.5% at 10-years) and head & neck tumors (rate 1.3% at 5-years, 1.9% at 10-years). Conclusions: Lung tumors and head & neck tumors are the most frequently observed SOT after LT.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33482364; info:eu-repo/semantics/altIdentifier/wos/WOS:000696803000021; volume:24; firstpage:1; lastpage:6; numberofpages:6; journal:ANNALS OF HEPATOLOGY; http://hdl.handle.net/11573/1576450Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85100412975

  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية

    المساهمون: Calvaruso V, Mazzarelli C, Milazzo L, Badia L, Pasulo L, Guaraldi G, Lionetti R, Villa E, Borghi V, Carrai P, Alberti A, Biolato M, Piai G, Persico M, Santantonio T, Felder M, Angelico M, Montalbano M, Mancusi RL, Grieco A, Angeli E, D'Offizi G, Fagiuoli S, Belli L, Verucchi G, Puoti M, Craxì A.

    مصطلحات موضوعية: HCV

    الوصف: We reported the efcacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in patients treated in the Italian compassionate-use program. 275 patients were included (202 male73.5%, mean age: 57.4 years, 62 HIV-coinfected, 94 with recurrence of hepatitis C post-OLT). Forty-nine patients (17.8%) had Child-Pugh B, Genotype(G) distribution was: G1a:72 patients (26.2%), G1b:137 (49.8%); G3:40 (14.5%) and G4:26 (9.5%). Patients received DCV with sofosbuvir(SOF) (n=221, 129 with ribavirin(RBV) or with simeprevir (SMV) or asunaprevir (ASU) (n=54, 19 with RBV) for up to 24 weeks. Logistic regression was used to identify baseline characteristics associated with sustained virological response at week 12 post-treatment (SVR12). Liver function changes between baseline and follow up were assessed in 228 patients. 240 patients achieved SVR12 (87.3%), post transplant and HIV co-infected patients were equally distributed among SVR and no SVR (35% vs 34.3%; p=0.56 and 24.2% vs 11.4%, p=0.13, respectively). SVR rate was signifcantly higher with the combination DCV+SOF compared with DCV+SIM or ASU (93.2% vs 63.0%, p<0.0001). Bilirubin value (OR: 0.69, CI95%: 0.54–0.87, p=0.002) and regimen containing SOF (OR: 9.99, CI95%: 4.09–24.40; p<0.001) were independently related with SVR. Mean albumin and bilirubin values signifcantly improved between baseline and follow-up week 12. DCV-based antiviral therapy was well tolerated and resulted in a high SVR when combined with SOF either in pre-transplant and in OLT patients and in “difcult to treat” HCV genotypes. Regimens containing DCV in combination with NS3 protease inhibitors obtained suboptimal results.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30679515; info:eu-repo/semantics/altIdentifier/wos/WOS:000456554600024; volume:9; issue:585; firstpage:1; lastpage:8; numberofpages:8; journal:SCIENTIFIC REPORTS; http://hdl.handle.net/10447/345341Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85060550956; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345835Test/

  9. 9
  10. 10
    دورية أكاديمية